Press Releases

2014.10.29 IR PDF (134KB)
Ranbaxy Q2 FY 2015 Sales Rs.32,180 Mn. H1 FY2015 Sales Rs.55,902 Mn
2014.10.15 IR PDF (125KB)
Announcement Regarding Submission of Tender Offer for Shares in Ambit Biosciences Corporation
2014.10.02 Corporate PDF (36KB)
Daiichi Sankyo (Thailand) Establishes Representative Office in Ho Chi Minh City, Vietnam
2014.10.01 Local (JPN) PDF (46KB)
Daiichi Sankyo and Daiichi Sankyo Espha Submit Supplemental New Drug Application in Japan for “Cravit® Tablets, Granules” and “Levofloxacin Tablets, Granules DSEP”
2014.09.30 Corporate PDF (20KB)
Daiichi Sankyo Appoints New Corporate Officers
2014.09.29 Corporate PDF (168KB)
Daiichi Sankyo to Acquire Ambit Biosciences
2014.09.26 Local (JPN) PDF (40KB)
Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA® (edoxaban) in Japan
2014.09.24 CSR PDF (26KB)
Daiichi Sankyo Selected for Dow Jones Sustainability Asia Pacific Index for the Fifth Consecutive Year
2014.09.03 R&D PDF (44KB)
Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes
2014.09.02 Local (JPN) PDF (58KB)
Launch of CANAGLU® Tablets 100mg
2014.09.01 R&D PDF (40KB)
Daiichi Sankyo Further Expands TaNeDS Collaborative Drug Discovery Program in Europe
2014.09.01 Local (JPN) PDF (37KB)
Daiichi Sankyo Espha Receives Manufacturing and Marketing License in Japan for “Levofloxacin Tablets 250mg/500mg” and “Granules 10% DSEP”
2014.08.28 Local (JPN) PDF (25KB)
Daiichi Sankyo Announces Cooperative Sales Agreement for the Recombinant Adsorbed Hepatitis B Vaccine “Bimmugen®”
2014.08.18 Local (JPN) PDF (18KB)
Initiation of Phase 3 Trial of CHS-0214 (Investigational Etanercept Biosimilar) in Japan (RApsody)
2014.08.07 Corporate PDF (98KB)
Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
2014.07.31 Local (JPN) PDF (57KB)
Daiichi Sankyo Concludes Basic Agreement for Transfer of Daiichi Sankyo Propharma Akita Plant and Decides Reorganization of Japanese Supply Chain Subsidiaries
2014.07.31 IR PDF (26KB)
Correction to the release titled "Ranbaxy Q1 FY 2015(Apr'14-Jun'14) Sales Rs.23.7 Bn"
2014.07.30 IR PDF (122KB)
Ranbaxy Q1 FY 2015 (Apr’14-Jun’14) Sales Rs.23.7 Bn Growth registered in Base business profitability
2014.07.08 Local (JPN) PDF (15KB)
Notice on Details of the Share Options
2014.07.04 Local (JPN) PDF (37KB)
Marketing and Manufacturing Approval in Japan Received for CANAGLU® Tablets 100mg
2014.07.04 Local (JPN) PDF (100KB)
Announcement on obtaining in Japan the marketing and manufacturing license for the 4-valent combination vaccine for the prevention of Pertussis, Diphtheria, Tetanus and Poliomyelitis (Polio) “Squarekids® subcutaneous injection syringe”
2014.07.02 Local (JPN) PDF (15KB)
12th Takamine Memorial Daiichi Sankyo Prize Winner Announced
2014.06.23 Local (JPN) PDF (117KB)
Daiichi Sankyo to Issue Share Options as Remuneration
2014.06.20 Local (JPN) PDF (176KB)
Daiichi Sankyo Launches New Generic Drugs Through Its Daiichi Sankyo Espha Subsidiary
2014.06.20 Local (JPN) PDF (18KB)
Daiichi Sankyo’s Japan Research Foundation for Clinical Pharmacology Awards Its 7th Annual Clinical Pharmacology Research Award
2014.06.11 Local (JPN) PDF (21KB)
Daiichi Sankyo Awarded a Japan Science and Technology Agency “Newly extended Technology transfer Program” Grant
2014.06.04 Corporate PDF (43KB)
Merger Between Sun Pharma and Daiichi Sankyo’s Subsidiary Ranbaxy (Additional Disclosure)
2014.05.27 Local (JPN) PDF (61KB)
Daiichi Sankyo Launches the Antiplatelet Agent Efient® 3.75mg/5mg Tablets
2014.05.26 Corporate PDF (402KB)
Dainippon Sumitomo Pharma and Daiichi Sankyo Cooperate on Lurasidone, an Atypical Antipsychotic Agent, in Four South American Countries
2014.05.23 Local (JPN) PDF (46KB)
Daiichi Sankyo Receives Approval in Japan for Additional Indication Related to RANMARKⓇ for Treatment of Giant Cell Tumor of Bone
2014.05.22 R&D PDF (140KB)
Sanford-Burnham and Daiichi Sankyo Form Alliance to Study Novel Drug Targets in Cardiovascular-Metabolic Diseases
2014.05.15 Corporate PDF (138KB)
Daiichi Sankyo Announces Changes to Representative Directors, Members of the Board, and Members of the Audit and Supervisory Board
2014.05.15 Local (JPN) PDF (15KB)
Daiichi Sankyo Announces Changes to Audit and Supervisory Board at Domestic Subsidiary
2014.05.12 IR PDF (1.61MB)
Ranbaxy January- March 2014 Sales at Rs.24.4 Bn
2014.04.25 Local (JPN) PDF (36KB)
Announcement Regarding the Post-evaluation Result for the Project of H5N1 Influenza Vaccine (the Initiative to Build Development and Production Capacity - the Japanese Ministry of Health, Labour and Welfare)
2014.04.25 Local (JPN) PDF (61KB)
Daiichi Sankyo Announces Discontinuation of Phase 3 Clinical Trial in Japan of Nimotuzumab (DE-766) in Lung Cancer
2014.04.11 Corporate PDF (118KB)
Announcement Regarding Merger Between Sun Pharma and Daiichi Sankyo’s Subsidiary Ranbaxy and Resulting Change in Subsidiary
2014.04.07 Corporate PDF (25KB)
Daiichi Sankyo Agrees to Vote its Shares in Ranbaxy in Favor of Sun Pharma’s Acquisition
2014.04.07 Corporate PDF (20KB)
Subpoena for Ranbaxy’s Toansa Plant
2014.04.03 R&D PDF (31KB)
Daiichi Sankyo and UC San Francisco Announce Collaboration in Drug Discovery Research for Neurodegenerative Diseases
2014.04.01 R&D PDF (50KB)
Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion
2014.03.31 Local (JPN) PDF (18KB)
Daiichi Sankyo Medical Representatives Improve Life-saving Knowledge and Skills
2014.03.25 Local (JPN) PDF (52KB)
Daiichi Sankyo to Facilitate New Drug Discovery in 2014 through Collaborative Research and Grants
2014.03.24 Local (JPN) PDF (47KB)
Daiichi Sankyo Receives Approval in Japan for Manufacturing and Marketing of the Antiplatelet Agent Efient® 3.75mg/5mg Tablets
2014.03.24 Local (JPN) PDF (46KB)
Subgroup Analysis of PRASFIT-ACS Study Evaluated Impact of Platelet Reactivity on Prevention of Ischemic Events in Perioperative Period of PCI
2014.03.24 R&D PDF (98KB)
Once-Daily Edoxaban Evaluated in Two Subgroup Analyses of East Asian Patients from the Largest Comparative Phase 3 Trials of a Novel Oral Anticoagulant
2014.03.19 R&D PDF (77KB)
Astellas Pharma and Daiichi Sankyo Form Compound Library Sharing Partnership
2014.03.17 Local (JPN) PDF (16KB)
Daiichi Sankyo Files NDA in Japan for Methaemoglobinaemia Injection Methylene Blue
2014.03.06 Local (JPN) PDF (89KB)
Announcement Regarding the Project of H5N1 Influenza Vaccines
2014.03.03 Corporate PDF (42KB)
Daiichi Sankyo Announces Organizational Restructuring as of April 1, 2014
2014.03.03 Corporate PDF (75KB)
Daiichi Sankyo Appoints New Group Corporate Officers
2014.02.25 Corporate PDF (16KB)
Updates on Toansa and Dewas plants of Ranbaxy
2014.02.14 R&D PDF (207KB)
Daiichi Sankyo and UMN Pharma Enter into Collaborative Research Agreement for Norovirus Vaccine
2014.02.06 IR PDF (110KB)
Ranbaxy Q4 FY14 Sales Rs.28.6 Bn. YTD Dec 2013 Sales Rs.106.0 Bn.
2014.01.31 IR PDF (99KB)
Voluntary Adoption of International Financial Reporting Standards (IFRS)
2014.01.24 Corporate PDF (17KB)
Update on Regarding the Import Alert on Ranbaxy’s Toansa Plant
2014.01.24 Corporate PDF (10KB)
Regarding the Import Alert on Ranbaxy’s Toansa Plant
2014.01.14 Corporate PDF (12KB)
Regarding Ranbaxy’s Toansa Plant
2014.01.09 R&D PDF (53KB)
Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
2014.01.09 R&D PDF (47KB)
Daiichi Sankyo Submits SAVAYSA(TM) (edoxaban) Tablets New Drug Application to the U.S. FDA for Once-Daily Use for Stroke Risk Reduction in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
2014.01.08 R&D PDF (65KB)
Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism

In order to view the PDF files, you need to have Adobe Reader 5.0 or later version installed.